July 2015 Monthly Test Updates

Published on 07/01/15

New Test Launches and Updates

The following new test is now available:

  • MM540 Hypercholesterolemia: Sequencing Panel. CPT codes also updated.

The following test updates are now live:

  • MD203 Paraganglioma-Pheochromocytoma: Deletion/Duplication Panel – Added FH
  • MM203 Paraganglioma-Pheochromocytoma: Sequencing Panel – Added FH
  • MD209 Gastrointestinal and Colorectal Cancer: Deletion/Duplication Panel – Added ATM, BLM, and POLD1
  • MM209 Gastrointestinal and Colorectal Cancer: Sequencing Panel – Added ATM, BLM, and POLD1. CPT codes also updated
  • MD205 High Risk Colorectal Cancer: Deletion/Duplication Panel – Added ATM, BLM, CDH1, and PTEN. CPT codes also updated
  • MM205 High Risk Colorectal Cancer: Sequencing Panel – Added ATM, BLM, CDH1, and PTEN. CPT codes also updated
  • MM208 Breast and Ovarian Cancer: Sequencing and Deletion/Duplication Panel – Added BARD1, MRE11A, RAD50, SMARCA4 (seq only), and XRCC2
  • MD200 Hereditary Cancer Syndrome: Deletion/Duplication Panel – Added BAP1, BARD1, BLM, BUB1B, MRE11A, POLD1, RAD50, SMARCB1, TSC1, TSC2, and XRCC2
  • MM200 Hereditary Cancer Syndrome: Sequencing Panel – Added BAP1, BARD1, BLM, BUB1B, MRE11A, POLD1, RAD50, SMARCA4, SMARCB1, TSC1, TSC2, and XRCC2
  • MD170 Skeletal Dysplasia: Deletion/Duplication Panel – Removed SLC25A12
  • MM170 Skeletal Dysplasia: Sequencing Panel – Removed SLC25A12 and added ACAN
  • MD171 Disproportionate Short Stature: Deletion/Duplication Panel – Removed SLC25A12
  • MM171 Disproportionate Short Stature: Sequencing Panel – Removed SLC25A12 and added ACAN
  • EXOMT Medical EmExome: Clinical Exome Sequencing, Family Trios – Removed mitochondrial genome sequencing
  • EXOME Medical EmExome: Clinical Exome Sequencing, Proband Only – Removed mitochondrial genome sequencing
  • MD240 Pulmonary Disease: Deletion/Duplication Panel – Removed MUC5B
  • MM240 Pulmonary Disease: Comprehensive Sequencing Panel – Removed MUC5B
  • MD242 Pulmonary Fibrosis and Hermansky-Pudlak Syndrome: Deletion/Duplication Panel – Removed MUC5B
  • MM242 Pulmonary Fibrosis and Hermansky-Pudlak Syndrome: Sequencing Panel – Removed MUC5B
  • MM310 Inherited Metabolic Disorders: Sequencing Panel – Added ALDH5A1
  • MM280 Neurology: Sequencing Panel – Added ALDH5A1
  • MM021 Autism Spectrum Disorders: Tier 2 Panel – Added ALDH5A1
  • MEPI1 Epilepsy and Seizure Disorders: Sequencing Panel – Added ALDH5A1
  • MD206 Renal Cancer: Deletion/Duplication Panel – Added BAP1, BUB1B, CDC73, MLH1, MSH2, MSH6, SDHC, SMARCB1, TP53, TSC1, and TSC2. CPT codes also updated
  • MM206 Renal Cancer: Sequencing Panel – Added BAP1, BUB1B, CDC73, MLH1, MSH2, MSH6, PMS2, SDHC, SMARCB1, TP53, TSC1, and TSC2. CPT codes also updated
  • MD402 Pancreatic Cancer: Deletion/Duplication Panel – Removed BAP1 and SMAD4; added VHL. CPT codes also updated
  • MM402 Pancreatic Cancer: Sequencing Panel – Removed BAP1 and SMAD4; added VHL

Test Requisitions - Things to Remember
Not completing a test requisition form entirely can sometimes lead to unnecessary delays in testing. Below are the most commonly missed items:

  • ICD9 codes
  • Policy holder name and date of birth
  • If any authorizations are obtained for the patient, please include a copy of the authorizations with the requisition.
  • Medicare patients must have a signed Advance Beneficiary Notice of Non-coverage (ABN) included with the requisition, except for following BRCA-related test codes: MM070, MM071, MM072, and MM208. Please note, EGL does not pre-verify benefits for patients with Medicare.
  • Signature in the “Authorization to Assign Benefits” section
  • Front and back copy of the patient’s insurance card
  • Billing pages - regardless of the person or entity to be billed, please complete this information.

Prior Authorization Reminder
When it is determined that a prior authorization is needed for testing, the sample will be placed on a billing hold. EGL will notify the client as to what is required and help with any necessary paperwork.

New and Updated Gene Panels

Industry-leading number of gene panels

EGL Next Generation Sequencing Panels include comprehensive, evidence-based gene lists, improved turnaround times, and reduced pricing.